P/B
0,5
Silo Pharma
SILO Pharma Inc is a developmental stage biopharmaceutical company developing novel therapeutics that address underserved conditions including stress-induced psychiatric disorders, chronic pain conditions, and central nervous system (CNS) diseases. It focuses on developing traditional therapies and psychedelic treatments in novel formulations and drug delivery systems. The company’s primary program, SPC-15, is an intranasal treatment targeting PTSD and stress-induced anxiety disorders.
SILO Pharma Inc is a developmental stage biopharmaceutical company developing novel therapeutics that address underserved conditions including stress-induced psychiatric disorders, chronic pain conditions, and central nervous system (CNS) diseases. It focuses on developing traditional therapies and psychedelic treatments in novel formulations and drug delivery systems. The company’s primary program, SPC-15, is an intranasal treatment targeting PTSD and stress-induced anxiety disorders.
$2.3M
Market Cap • 10/2/2026
2010
(16 years)
Founded
2012
(14 years ago)
IPO
NASDAQ
Listing Exchange
United States
Country
Valuation
P/S
42,8
P/EBITDA
—
P/OCF
—
P/FCF
—
P/E
—
BVPS
3,1
EPS
—
Market Cap
Market Cap
2,3M
EV
-3,1M
EV/Revenue
-57,6
EV/EBITDA
0,7
EV/EBIT
0,7
Payout
Dividend Per Share
0
Dividend Yield
0%
Buyback Yield
0%
Total Yield
0%
Payout
0%
Retained Earnings
-22M
Profitability
Gross Margin
—
EBITDA Margin
—
EBIT Margin
—
Net Margin
—
D&A/EBITDA
0%
R&D/Revenue
3996,7%
Capex/Revenue
0%
Capex/D&A
0%
Capex/OCF
0%
SBC/OCF
—
% PPE
0%
% Goodwill
0%
ROE
—
ROIC
—
Growth
CAGR Revenue 5Y
10,6%
CAGR Op. Income 5Y
57,4%
CAGR Net Income 5Y
13,2%
CAGR EPS 5Y
-32,5%
CAGR OCF 5Y
15%
Leverage
N.D./EBITDA
1,2
Debt/Equity
0%
Current Ratio
5,4
Quick Ratio
5,1
Interest Coverage
—
Premium
- Unrestricted access
- Unlimited data history
- Analysis videos
- Quarterly highlights
- Customizable financials table
- Ranking
- Discussions
...and much more!